Bayer Healthcare's key therapy areas of focus are oncology, cardiology, ophthalmology and women's health, according to vice-president and head of early licensing Dr. Mark Wolters; but while the company is investing in programs in these areas at all stages of development, it has to keep its lasers focused and can't step into unapproved zones.
Bayer Healthcare's key therapy areas of focus are oncology, cardiology, ophthalmology and women's health, according to vice-president and head of early licensing Dr. Mark Wolters; but while the company is investing in programs in these areas at all stages of development, it has to keep its lasers focused and can't step into unapproved zones.
"There are a few areas where we are not active, like pain treatment for instance, also Alzheimer's disease and the...
Wales-based group launches with $140m series A.
Supernus agreed to pay $561m upfront plus a contingent value right that could add $234m to buy Sage, topping a previously rejected offer from Biogen.
Open-label extension data have persuaded Roche to move prasinezumab into Phase III, where it believes a few tweaks to the study design could turn a near miss into success.
The Phase II TREM2 agonist is not part of Sanofi’s planned acquisition.
With two deaths in non-ambulatory DMD patients, Sarepta is attempting damage control and will ask the US FDA to advise, setting up a possible confrontation with CBER director Prasad.
Supernus agreed to pay $561m upfront plus a contingent value right that could add $234m to buy Sage, topping a previously rejected offer from Biogen.
The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.
